+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Certolizumab"

Arthritis Monoclonal Antibodies Global Market Report 2024 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Ankylosing Spondylitis - Pipeline Insight, 2024 - Product Thumbnail Image

Ankylosing Spondylitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
From
From
From
CIMZIA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CIMZIA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
From
From
KOL Perspectives: Treatment strategies for pregnant RA patients - Product Thumbnail Image

KOL Perspectives: Treatment strategies for pregnant RA patients

  • Drug Pipelines
  • July 2018
  • 27 Pages
  • Global
From
From
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Loading Indicator

Certolizumab is a monoclonal antibody used to treat immune disorders. It is used to treat a variety of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It works by blocking the action of a protein called tumor necrosis factor (TNF), which is involved in the body's inflammatory response. Certolizumab is administered as an injection, usually once every two weeks. Certolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is one of several drugs used to treat immune disorders, and is often used in combination with other medications. It is generally well-tolerated, with few side effects. Some companies in the Certolizumab market include UCB, Pfizer, and AbbVie. Show Less Read more